Want to see FR:ALTHX full AI Analyst Report?
Top Page
Theranexus SA
(ALTHX)
Select Model
Select Model
Rating:46Neutral
Price Target:
€3.50
▲(72.41% Upside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by weak financial performance, including ongoing losses, persistent cash burn, and the 2025 revenue collapse (high funding and execution risk). Technicals provide some support because the stock is above key moving averages, but momentum indicators are not convincingly positive. Valuation remains pressured by negative earnings and no indicated dividend support.
Positive Factors
CNS / rare-disease focus with partner-driven model
A focused CNS and rare-disease strategy concentrates R&D on high unmet-need niches where clinical wins can command premium positioning. Coupling clinical-stage programs with partnerships helps spread development risk and conserve internal resources, a durable advantage for a small biotech.
Negative Factors
Chronic negative cash generation
Persistent negative operating and free cash flow forces repeated external financing or asset sales. Over months this erodes strategic optionality, risks dilutive capital raises, and constrains the ability to fund multi-year clinical programs without partner or investor support.
Read all positive and negative factors
Positive Factors
Negative Factors
CNS / rare-disease focus with partner-driven model
A focused CNS and rare-disease strategy concentrates R&D on high unmet-need niches where clinical wins can command premium positioning. Coupling clinical-stage programs with partnerships helps spread development risk and conserve internal resources, a durable advantage for a small biotech.
Read all positive factors
Theranexus SA (ALTHX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€47.79M
Dividend YieldN/A
Average Volume (3M)133.77K
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees12
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume147,352
30 Day Avg. Volume133,766
Financial Highlights & Ratios
PEG Ratio-2.04
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.84
Revenue Forecast (FY)N/A
Theranexus SA Business Overview & Revenue Model
Company Description
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluatio...
How the Company Makes Money
null...
Theranexus SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.28M | 296.33K | 414.90K | 602.00 |
| Gross Profit | -108.60K | -333.55K | -4.64M | 82.90K | -8.82M |
| EBITDA | -10.12M | -2.53M | -7.39M | -5.93M | -8.67M |
| Net Income | -3.00M | -1.77M | -6.83M | -6.57M | -8.15M |
Balance Sheet | |||||
| Total Assets | 10.54M | 3.74M | 7.24M | 12.05M | 16.89M |
| Cash, Cash Equivalents and Short-Term Investments | 7.77M | 966.59K | 4.90M | 9.11M | 12.53M |
| Total Debt | 2.88M | 2.87M | 3.64M | 4.89M | 5.33M |
| Total Liabilities | 7.64M | 5.40M | 5.02M | 6.33M | 6.71M |
| Stockholders Equity | 1.99M | -1.66M | 2.22M | 5.73M | 10.18M |
Cash Flow | |||||
| Free Cash Flow | -939.81K | -3.40M | -6.40M | -5.41M | -6.40M |
| Operating Cash Flow | -883.76K | -3.37M | -6.36M | -5.37M | -6.25M |
| Investing Cash Flow | -168.23K | 77.04K | -61.11K | 323.53K | -150.62K |
| Financing Cash Flow | 7.85M | -646.42K | 2.22M | 1.63M | 7.71M |
Theranexus SA Technical Analysis
Neutral
2.03
Price Trends
3.41
Negative
3.32
Negative
2.72
Positive
Market Momentum
-0.03
Positive
48.53
Neutral
35.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHX, the sentiment is Neutral. The current price of 2.03 is below the 20-day moving average (MA) of 3.32, below the 50-day MA of 3.41, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 35.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALTHX.
Theranexus SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €1.06B | -32.31 | ― | ― | -23.21% | -46.17% | |
46 Neutral | €47.79M | -15.05 | ― | ― | ― | ― | |
45 Neutral | €18.80M | -0.99 | 51.23% | ― | -99.93% | 44.53% | |
43 Neutral | €130.61M | -2.59 | -40.00% | ― | ― | -5.60% | |
41 Neutral | €12.72M | -1.18 | -4411.84% | ― | 31.94% | -90.36% | |
40 Underperform | €53.52M | -19.52 | ― | ― | 9.51% | 73.33% |
* Healthcare Sector Average
FR:ALTHX
Theranexus SA
3.31
2.35
244.43%
FR:SIGHT
GenSight Biologics SA
0.08
-0.07
-47.71%
FR:AB
AB Science SA
0.77
-0.71
-47.89%
FR:ALSEN
Sensorion SAS
0.25
-0.05
-16.23%
FR:ALINS
Intrasense SA
0.24
-0.05
-16.61%
FR:MEDCL
MedinCell SA
29.40
12.95
78.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.